series-b
Stage
3
Investors
About
Sol-Gel Technologies is an Israeli biopharmaceutical company that develops topical dermatological drugs for conditions such as acne, rosacea, and rare skin diseases. Its approved products Twyneo® and Epsolay® are marketed in the US by Galderma, and its pipeline includes topical patidegib for Gorlin syndrome.
Explore Sol-Gel Technologies Ltd's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.